Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRevolution Beauty Regulatory News (REVB)

Share Price Information for Revolution Beauty (REVB)

Share Price is delayed by 15 minutes
Get Live Data
4.86    -0.02 (-0.41%)
Bid:
4.86
Ask:
5.00
Spread: 0.14 (2.881%)
Market Cap: £42.27m
REVB Live PriceLast checked at - London Stock Exchange

Intraday Revolution Beauty Share Chart

Response to allegations by Chrysalis Investments

22 Apr 2024 09:09

RNS Number : 4971L
Revolution Beauty Group PLC
22 April 2024
 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR

 

For immediate release

22 April 2024

Revolution Beauty Group plc

("Revolution Beauty", the "Group", or the "Company")

Response to allegations by Chrysalis Investments Limited

Revolution Beauty (AIM: REVB), the multi-channel mass beauty innovator, notes the comments by Chrysalis Investments Limited ("Chrysalis") this morning, stating that it issued draft particulars of claim to the Company on 19 April 2024.

On 2 February 2024, the Company announced an initial response to allegations made by Chrysalis. The Company now confirms that, on 19 April 2024, it received a further letter from Chrysalis' legal advisers, including draft particulars of Chrysalis' alleged claims and details of the quantum of Chrysalis' thereof, which are as stated in Chrysalis' announcement of this morning. The draft particulars of claim note a claim of £39m, together with a claim for consequential losses of a further £6.2m. No claim has yet been filed with the court.

The Company, as previously maintained, strongly contests the allegations. The Company and its legal advisers continue to review the materials received on 19 April 2024, and is considering its response. The Company will continue to engage with Chrysalis and its advisers accordingly.

Further updates will be provided as appropriate.

 

For further information, please contact:

 

Investor Relations

Lauren Brindley, CEO

Neil Catto, CFO

Investor.Relations@revolutionbeautyplc.com

 

Joint Corporate Brokers

Liberum (NOMAD): Edward Thomas / Dru Danford / John More

Tel: +44 (0) 203 100 2222

 

Zeus: Nick Cowles / Jamie Peel / Jordan Warburton

Tel: +44 (0) 161 831 1512

 

Media enquiries

Headland Consultancy: Matt Denham / Antonia Pollock

Tel: +44 (0)20 3805 4822

Revolutionbeauty@headlandconsultancy.com

 

The person responsible for arranging the release of this announcement on behalf of the Company is Lauren Brindley, the Chief Executive Officer of the Company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPEAPLAAELLEEA
Date   Source Headline
8th Jun 20267:00 amRNSNew Licensing Partnership with Debenhams Group
5th Jun 20267:00 amRNSFinancial Conduct Authority Update
16th Apr 20267:00 amRNSGrant of Share Options
1st Apr 202611:35 amRNSTotal Voting Rights
11th Mar 20267:00 amRNSAppointment of Nominated Adviser
2nd Mar 202611:28 amRNSTotal Voting Rights
3rd Feb 20264:05 pmRNSTotal Voting Rights
3rd Feb 20264:05 pmRNSBLOCK LISTING SIX MONTHLY RETURN
2nd Jan 20263:48 pmRNSTotal Voting Rights
15th Dec 20256:18 pmRNSDirector/PDMR Shareholding
1st Dec 20255:43 pmRNSTotal Voting Rights
27th Nov 20253:59 pmRNSDirector/PDMR Shareholding
27th Nov 20257:00 amRNSInterim Results
26th Nov 20256:15 pmRNSRelated Party Transaction
4th Nov 20254:32 pmRNSTotal Voting Rights
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20259:33 amRNSResult of AGM
24th Sep 20257:00 amRNSDirectorate Change
18th Sep 20257:00 amRNSHolding(s) in Company
17th Sep 202512:30 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSDirector/PDMR Shareholding
16th Sep 20255:17 pmRNSHolding(s) in Company
16th Sep 20259:11 amRNSHolding(s) in Company
11th Sep 20254:09 pmRNSResults of General Meeting
2nd Sep 20258:30 amRNSTotal Voting Rights
1st Sep 20255:06 pmRNSHolding(s) in Company
1st Sep 20258:33 amRNSHolding(s) in Company
29th Aug 20254:50 pmRNSFinal Results, Annual Report Posting & AGM Notice
26th Aug 20257:01 amRNSCircular Publication, Notice of GM & Board Update
26th Aug 20257:00 amRNSResult of Retail Offer to existing shareholders
22nd Aug 20254:31 pmRNSPDMR Dealing
22nd Aug 20253:30 pmRNSHolding(s) in Company
22nd Aug 20258:52 amRNSHolding(s) in Company
22nd Aug 20258:40 amRNSRetail Offer to existing shareholders
22nd Aug 20258:09 amRNSResult of Placing and Subscription
22nd Aug 20257:02 amRNSProposed Placing and Subscription via ABB
22nd Aug 20257:01 amRNSPreliminary Unaudited Results
22nd Aug 20257:00 amRNSTermination of Formal Sale Process
21st Aug 202510:51 amRNSForm 8.5 (EPT/RI)
20th Aug 202510:28 amRNSForm 8.5 (EPT/RI)
19th Aug 202512:27 pmRNSFY25 Trading Update
19th Aug 202510:01 amRNSForm 8.5 (EPT/RI)
18th Aug 202510:27 amRNSForm 8.5 (EPT/RI)
15th Aug 20254:11 pmRNSHolding(s) in Company
15th Aug 20259:57 amRNSForm 8.5 (EPT/RI)
14th Aug 202510:25 amRNSForm 8.5 (EPT/RI)
13th Aug 202510:31 amRNSForm 8.5 (EPT/RI)
12th Aug 202510:05 amRNSForm 8.5 (EPT/RI)
11th Aug 202510:26 amRNSForm 8.5 (EPT/RI)
8th Aug 202511:31 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.